Texas Oncology

CURE Media Group and Oncology Nursing News Announces the 2024 Extraordinary Healer® Award Finalists

Retrieved on: 
Friday, March 15, 2024
RN, Health, Washington Convention Center, Haematopoietic system, Mentorship, Oncology Nursing Society, Environment, Simmons University, Caregiver, Dana–Farber Cancer Institute, Education, Patient, Research, Transport, Cancer, Wonders, Texas Oncology, Survivor, OSN, Pediatrics, Johnson & Johnson, Media Group, Kidney, Multimedia, Ochsner Health System, Nursing, OCN

This award honors oncology nurses whose compassion and expertise improve the lives of their patients.

Key Points: 
  • This award honors oncology nurses whose compassion and expertise improve the lives of their patients.
  • The award presentations and winner announcement will be held on April 24, 2024 during the Oncology Nursing Society's Annual Congress at The Walter E. Washington Convention Center in Washington, DC.
  • The finalists for the 2024 Extraordinary Healer award are:
    Jessica McDade, B.S.N., RN, OCN.
  • For more information on the 2024 Extraordinary Healer event and to register, please visit the event page .

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results

Retrieved on: 
Friday, January 12, 2024
Conference call, Texas Oncology, Cancer, Patient, Conference, Research, WAM

FLORHAM PARK, N.J., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host a conference call with M. Yair Levy, M.D., director of hematologic malignancies research at Texas Oncology and investigator in the CLOVER WaM pivotal study of iopofosine I 131, on Friday, January 19, 2024 at 8:30 a.m.

Key Points: 
  • FLORHAM PARK, N.J., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host a conference call with M. Yair Levy, M.D., director of hematologic malignancies research at Texas Oncology and investigator in the CLOVER WaM pivotal study of iopofosine I 131, on Friday, January 19, 2024 at 8:30 a.m.
  • ET.
  • Dr. Levy will join the Cellectar management team to discuss his perspective, as a community-based hemotologist, on the positive topline results of iopofosine I 131 in patients with relapsed/refractory Waldenstrom’s macroglobulinemia, announced on January 8, 2024.
  • Details for the call are as follows:
    Conference call & Webcast Details:

Sarah Cannon Research Institute to Present Latest Research Insights at the 2023 ASH Annual Meeting & Exposition

Retrieved on: 
Thursday, December 7, 2023
Health, Science, Research, Clinical Trials, Oncology, HCA Healthcare, Methodist Hospital, Annual general meeting, PST, St. Elizabeth Healthcare (Kentucky), Sickle cell disease, Bone marrow, ASH, BMT, BSN, Malignancy, Exposition, Sarah Cannon Research Institute, SCRI, Abstract, Nursing care plan, Nivolumab, Society, Physician, Monomethyl auristatin E, Safety, McKesson Corporation, Pharmaceutical industry, Nursing, Vaccine, Dacarbazine, MD, Doxorubicin, Texas Oncology, Patient

Sarah Cannon Research Institute ( SCRI ) announced today that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition .

Key Points: 
  • Sarah Cannon Research Institute ( SCRI ) announced today that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition .
  • Hosted in San Diego and online from Dec. 9-12, the meeting is the year’s most comprehensive global hematology event.
  • At this year’s ASH Annual Meeting & Exposition, SCRI investigators, including physicians from The US Oncology Network , will discuss groundbreaking research in malignant and non-malignant blood cancer, CAR T-Cell therapy, real-world outcomes, and targeted immunotherapies.
  • Investigators highlighting research at this year’s ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, and partners from The US Oncology Network and Ontada.

Carrum Health and Texas Oncology Collaborate on New Breast Cancer Treatment Model

Retrieved on: 
Wednesday, November 15, 2023
Breast cancer, Immunotherapy, Cancer, Patient, Radiation, SAN, Center of excellence, Toxicity, Carrum, Victoria, Medical imaging, Health insurance, DALLAS, Texas Oncology

SAN FRANCISCO and DALLAS, Nov. 15, 2023 /PRNewswire/ -- Carrum Health, a value-based Centers of Excellence healthcare solution changing how we pay for and deliver cancer and surgical care, and Texas Oncology, one of the largest community-based oncology practices in the U.S., today announced a new collaboration to provide high-quality, cost-effective breast cancer care to patients. Through employers, Carrum Health will offer patients a bundled package for breast cancer care that includes two years of coverage for chemotherapy, radiation, and symptom management from Texas Oncology.

Key Points: 
  • Through employers, Carrum Health will offer patients a bundled package for breast cancer care that includes two years of coverage for chemotherapy, radiation, and symptom management from Texas Oncology.
  • "About half of cancer care is delivered in community oncology settings, which makes these providers a critical component in expanding access to high-value cancer care to our members," said Sach Jain, Carrum Health founder and CEO.
  • With the market's only all-inclusive cancer care bundles, Carrum Health offers access to comprehensive breast cancer treatment and follow-up care including all cancer-related costs, such as chemotherapy and immunotherapy, which are high-cost drivers.
  • In addition, Carrum Health and Texas Oncology plan to expand this collaboration to include other cancers, ensuring more Texans are able to benefit from high-value cancer care.

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

Retrieved on: 
Saturday, October 14, 2023
Multimedia, M&T Bank, Priority review, Cancer, Glomus tumor, Food, Doctor of Philosophy, Hope, Research, Roswell Park Comprehensive Cancer Center, Texas Oncology, Ride, Multiple myeloma, Roswell, MD, Fred Hutchinson Cancer Research Center, National Cancer Institute, University, Survival, Disease, FDA, Glioblastoma, Accelerated approval (FDA), Fast track (FDA), NDA, Neurosurgery, Overlook Medical Center, Northwell Health, Journal, FTD, Fast Track, Assistant, PSA, Regulation of tobacco by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, Principal investigator, Prostate cancer, Brain, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical imaging, Medical device, Online shopping, DRS, Upstate New York, New York University, Roswell Park

BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The designation awarded to MimiVax Inc. provides more extensive and accelerated access to FDA resources for the company's development of the novel cancer immunotherapy SurVaxM, which is now in late-stage trials around the country.

Key Points: 
  • The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park.
  • BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

Retrieved on: 
Thursday, October 12, 2023
Priority review, Texas Oncology, UCSF, Fred Hutchinson Cancer Research Center, Disease, FDA, Science in newly industrialized countries, Accelerated approval (FDA), NDA, Overlook Medical Center, Journal, Northwell Health, FTD, Fast Track, NYU, American Journal of Clinical Oncology, Roswell Park, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical device, Glioblastoma

BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).

Key Points: 
  • BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).
  • MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma.
  • MimiVax is focused on completing the Phase 2b SURVIVE study and securing funding necessary to bring SurVaxM through the FDA approval process.
  • "The receipt of Fast Track Designation affirms the importance of new clinical developments of novel therapies to improve the treatment and outcomes for patients with newly diagnosed glioblastoma," said Michael Ciesielski, CEO of MimiVax.

Susan G. Komen® To Host MORE THAN PINK Walk in Austin This Fall

Retrieved on: 
Tuesday, October 3, 2023
Walkers, THAN, Dell Technologies, Texas Oncology, Patient, Susan, Breast cancer, Disease, Medical imaging, Central Texas

AUSTIN, Texas, Oct. 3, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, today announced it will host a MORE THAN PINK Walk in Central Texas this fall. The Austin MORE THAN PINK Walk will take place on Sunday, Oct. 29, 2023.

Key Points: 
  • AUSTIN, Texas, Oct. 3, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, today announced it will host a MORE THAN PINK Walk in Central Texas this fall.
  • The Austin MORE THAN PINK Walk will take place on Sunday, Oct. 29, 2023.
  • "We look forward to welcoming walkers to make a difference in our fight against breast cancer," said Monique Stensrud, executive director at Susan G. Komen.
  • This year's Austin MORE THAN PINK Walk is made possible by the following sponsors: Dell Technologies, Texas Oncology, Clinical Pathology Laboratories, H-E-B and Austin Radiological Association, Auctane, Evamor, Natrelle, Walmart and Grove Wine Bar & Kitchen.

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Retrieved on: 
Friday, May 26, 2023
MSD, Senior, Hepatocellular carcinoma, Pharming, Sunitinib, Survival, Head, DO, Cancer, Patient, Stomatitis, Risk, Merck, Fatigue, Texas Oncology, Diarrhea, Pembrolizumab, FACP, Research, Lung cancer, Merck & Co., Hypertension, LEAP, HIV disease progression rates, Esophageal cancer, Abstract, Death, Apoptosis, Lenvatinib, Overalls, PFS, Eisai, CR, Stomach, ORR, Acral lentiginous melanoma, Arm, Progression-free survival, RCC, CI, OS, Drug, Trae tha Truth, Hypothyroidism, ASCO, Central Time Zone, American Society of Clinical Oncology, Cancer Treatment Centers of America, Physician, Annual general meeting, Nausea, Society, Pharmaceutical industry, EU

After four years of follow-up, LENVIMA plus KEYTRUDA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).

Key Points: 
  • After four years of follow-up, LENVIMA plus KEYTRUDA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).
  • The 24- and 36-month estimated OS rates were 80.4% and 66.4% for LENVIMA plus KEYTRUDA versus 69.6% and 60.2% for sunitinib, respectively.
  • Grade ≥3 treatment-related adverse events (TRAE) occurred in 74.1% of patients who received LENVIMA plus KEYTRUDA versus 60.3% of patients who received sunitinib.
  • These findings reinforce the important role of LENVIMA plus KEYTRUDA as a first-line standard of care treatment option for patients with advanced renal cell carcinoma."

NexCore Group-developed Cancer Center opens in Amarillo, TX

Retrieved on: 
Friday, July 14, 2023
Real estate development, Texas Oncology, Friends, Perkins and Will, Radiation, Colon, Oncology, Science, Surgical oncology, Patient, Hematology, Health, Family, Hospital, Medical imaging, Nursing

DENVER, July 13, 2023 /PRNewswire-PRWeb/ -- NexCore Group, a national healthcare, life sciences, and senior living real estate developer, announced they celebrated the grand opening of the new Texas Oncology-Amarillo, a comprehensive cancer center serving the residents in the panhandle of Texas. In collaboration with Texas Oncology, the NexCore team led the single-story, 50,000-square-foot build-to-suit cancer center from concept to construction.

Key Points: 
  • In collaboration with Texas Oncology, the NexCore team led the single-story, 50,000-square-foot build-to-suit cancer center from concept to construction.
  • The new Texas Oncology-Amarillo cancer center significantly increases access to care to meet the growing need in the Texas panhandle.
  • NexCore Group Chief Development Officer Todd Varney says the firm is honored to have partnered with Texas Oncology to create a new center of excellence designed to deliver comprehensive cancer treatment with the capacity for innovative clinical trials and cancer research.
  • This facility allows patients to receive modern cancer care from local oncology experts, supported by family and friends within their community.

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Retrieved on: 
Sunday, June 4, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Puma Biotechnology, Translational Genomics Research Institute, MYC, City of Hope, TP53, Texas Oncology, Unfolded protein response, Progression-free survival, Metastasis, HER2, Neoplasm, Paclitaxel, Biomarker, RNA, PFS, Trial of the century, AKT1, ASCO, HR, City, American Society of Clinical Oncology, Patient, Breast cancer, MBC, Baylor University Medical Center, Annual general meeting, Puma, Cancer, UPR, AURKA, Poster, CDT, Research, Phase, Abstract, Woman, Gene, Society, JAMA Network Open, CDH1, Disease, Pharmaceutical industry, Vaccine, Medical imaging, PIK3CA

(Jama Network Open, April 2021) and showed that the addition of alisertib to paclitaxel improved progression-free survival (PFS) among enrolled patients compared with paclitaxel alone (HR, 0.56; 95%CI, 0.37-0.84; P = .005).

Key Points: 
  • (Jama Network Open, April 2021) and showed that the addition of alisertib to paclitaxel improved progression-free survival (PFS) among enrolled patients compared with paclitaxel alone (HR, 0.56; 95%CI, 0.37-0.84; P = .005).
  • No mutations were significantly associated with response or resistance to alisertib plus paclitaxel, including those in PIK3CA, TP53, AKT1, HER2, and CDH1.
  • Increased MYC RNA expression was not observed in patients who did not appear to benefit from alisertib plus paclitaxel.
  • This biomarker analysis will be very helpful to the design of the future trials of alisertib that we are planning in hormone receptor positive HER2-negative breast cancer.”